Carmat (ALCAR) - Regulatory agency suspends Carmat implants

11:41 EST 1 Dec 2016 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Carmat: On 30 November, Carmat announced that the first patient implanted with its bioprosthetic heart as part of its European pivotal trial has died. The implantation occurred in late August and press sources report that the death was in October. The company’s analyses do not suggest the prosthesis was responsible for the death, although the French regulatory agency (ANSM) is suspending future Carmat implantations. Our valuation (previous rNPV of €747m) is under review.
ISIN: FR0010907956

Original Article: Carmat (ALCAR) - Regulatory agency suspends Carmat implants


More From BioPortfolio on "Carmat (ALCAR) - Regulatory agency suspends Carmat implants"

Quick Search

Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...